MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced that The Society of Thoracic Surgeons (STS) has endorsed its Advanced Ablation course for both physicians and fellows. The course provides surgeons and other medical professionals with […]
Other News
InspireMD Announces Fourth Quarter 2018 Financial Results
TEL AVIV, Israel, Feb. 19, 2019 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced results for the fourth quarter ending December 31, 2018. Fourth Quarter 2018 and […]
Stereotaxis to Participate in BTIG Healthcare Investor Conference
ST. LOUIS, Feb. 19, 2019 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and Chief Executive Officer, is scheduled to participate in the BTIG Healthcare Investor Conference in Snowbird, UT, on February […]
CHF Solutions Enters the South American Market with a Distribution Agreement with Bragenix LTDA in Brazil
EDEN PRAIRIE, Minn., Feb. 19, 2019 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), today announced the initiation of a distribution agreement in the Brazilian market with Bragenix, LTDA. This agreement expands the company’s worldwide sales outreach into South America by entering the largest market in the region. “We have aggressively […]
Final Patient Dosed in Mesoblast Phase 3 Trial of Revascor Cell Therapy for Advanced Heart Failure
NEW YORK and MELBOURNE, Australia, Feb. 19, 2019 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a world leader in development and commercialization of cellular medicines, announced today that the last patient has now been dosed in the Phase 3 events-driven trial of its allogeneic cell therapy product candidate Revascor for advanced chronic […]
Hancock Jaffe Successfully Starts First-in-Human VenoValve Study
IRVINE, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a Company specializing in medical devices that restore cardiac and vascular health, today announced the successful start of its VenoValve® first-in-human study in Bogota, Colombia. The first VenoValve was implanted in a patient and the procedure […]
Medtronic Reports Third Quarter Financial Results
DUBLIN – February 19, 2019 – Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2019, which ended January 25, 2019. The company reported third quarter worldwide revenue of $7.546 billion, an increase of 2.4 percent as reported or 4.4 percent on an organic basis, […]
Philips launches Zenition mobile C-arm platform for enhanced operating room performance and workflow efficiency
AMSTERDAM, Feb. 18, 2019 /PRNewswire/ — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Philips Zenition, its new mobile C-arm imaging platform. Mobile C-arms are X-ray systems that are brought into the operating room (OR) to provide live image guidance during a wide range of surgeries including […]
Affluent Medical Releases Impressive Results from Scope 1 Clinical Trial Validating Efficacy of KARDIOZIS Technology
PARIS–(BUSINESS WIRE)–Affluent Medical (Paris:ALAM), a French medtech company specialized in innovative, minimally invasive implants designed to restore key physiological functions for patients suffering from heart and vascular diseases, as well as urinary incontinence, today announces positive results from its SCOPE 1 clinical trial validating the efficacy of KARDIOZIS technology. Results have been […]
Foldax, Inc. Gains Approval to Begin US Clinical Trials of the First and Only Biopolymer Heart Valve Platform
SALT LAKE CITY–(BUSINESS WIRE)–Foldax, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted IDE approval to begin an Early Feasibility Study of the Tria surgical aortic heart valve for the treatment of aortic valve disease. Using breakthrough LifePolymer™ – a proprietary advanced biopolymer material – and […]



